Christopher Y Thomas
Overview
Explore the profile of Christopher Y Thomas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
399
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bitting R, Tooze J, Goodman M, Vile D, Brown J, Thomas C, et al.
Cancer Res Commun
. 2024 Feb;
4(2):530-539.
PMID: 38345536
Purpose: Single-agent checkpoint inhibition is effective in a minority of patients with platinum-refractory urothelial carcinoma; therefore, the efficacy of combining low-dose paclitaxel with pembrolizumab was tested. Materials And Methods: This...
2.
Bitting R, Tooze J, Isom S, Petty W, Grant S, Desnoyers R, et al.
Am J Clin Oncol
. 2021 Apr;
44(6):239-246.
PMID: 33867481
Objective: Preclinical studies with muscadine grape extract (MGE) show antitumor activity and decreased systemic inflammation. This phase I study (NCT02583269) assessed safety and tolerability of a proprietary MGE preparation in...
3.
Peak T, Fenu E, Rothberg M, Thomas C, Davis R, Levine E
Case Rep Urol
. 2020 Nov;
2020:8846135.
PMID: 33204569
Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present...
4.
Ferrarotto R, William Jr W, Tseng J, Marur S, Shin D, Murphy B, et al.
Oral Oncol
. 2018 Jun;
82:83-90.
PMID: 29909907
Objectives: Cixutumumab (CIX) and cetuximab (CET) monoclonal antibodies block ligand-binding to insulin-like growth factor-1 receptor (IGF-1R) and epidermal growth factor receptor (EGFR) respectively. The objective of this study was to...
5.
Dillon P, Petroni G, Horton B, Moskaluk C, Fracasso P, Douvas M, et al.
Clin Cancer Res
. 2017 Apr;
23(15):4138-4145.
PMID: 28377480
Genetic and preclinical studies have implicated FGFR signaling in the pathogenesis of adenoid cystic carcinoma (ACC). Dovitinib, a suppressor of FGFR activity, may be active in ACC. In a two-stage...
6.
Dillon P, Chakraborty S, Moskaluk C, Joshi P, Thomas C
Head Neck
. 2014 Dec;
38(4):620-7.
PMID: 25487882
Background: Adenoid cystic carcinoma (ACC) is a rare tumor of secretory glands. In this study, recent advances in molecular characterization and in therapeutics are reviewed. Methods: A search of articles...
7.
8.
Liu W, Xie C, Thomas C, Kim S, Lindberg J, Egevad L, et al.
Cancer
. 2013 Apr;
119(13):2405-12.
PMID: 23609948
Background: This study sought to identify novel effectors and markers of localized but potentially life-threatening prostate cancer (PCa), by evaluating chromosomal copy number alterations (CNAs) in tumors from patients who...
9.
Jameson M, Taniguchi L, Vankoevering K, Stuart M, Francom C, Mendez R, et al.
J Oral Pathol Med
. 2012 Oct;
42(4):332-8.
PMID: 23106397
Background: Although oral squamous cell carcinomas (OSCCs) commonly overexpress the epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitors (TKIs) exhibit poor efficacy clinically. Activation of the insulin-like growth factor-1...
10.
Hollen P, Gralla R, Jones R, Thomas C, Brenin D, Weiss G, et al.
Support Care Cancer
. 2012 Oct;
21(3):889-99.
PMID: 23052911
Purpose: Appropriate utilization of treatment is a goal for all patients undergoing cancer treatment. Proper treatment maximizes benefit and limits exposure to unnecessary measures. This report describes findings of the...